Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia

NCT02351037 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02351037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2015
Completion date
April 30, 2017
Enrollment
36 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)